author-photo

Sylvia Zhao

Novartis

14

Papers

275

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

New paradigm for expediting drug development in Asia

2020 Drug Discovery Today
Show All
- Source
- Cite
- Save
Citations (2)
Absorption, Distribution, Metabolism, and Excretion (ADME) of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.

2020 Drug Metabolism and Disposition
Show All
- Source
- Cite
- Save
Citations (5)
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment.

2020 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (4)
The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

2019 Leukemia
Show All
- Source
- Cite
- Save
Citations (22)
Expediting access to medicines in Asia: Recommendations for a new paradigm of global drug development

2019
Show All
- Source
- Cite
- Save
Citations (0)
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

2019 Journal of Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (8)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (130)
ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA

2017 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (1)
P1.04Phase I dose escalation and expansion study to evaluate safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (42)